Print this page    •   Back to Web version of article

The Body Covers: The 12th International AIDS Conference

Poster Session 22343: A Phase III, Double-Blind, Placebo-Controlled, Multi-Center Study to Determine the Effectiveness and Tolerability of the Combination of Efavirenz and Indinavir (IDV) versus Indinavir in HIV-1 Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy at 24 Weeks

Coverage provided by Michael Giordano, M.D.

June 30, 1998

This study of 300 patients with at least 8 weeks of experience with nucleoside reverse transcriptase inhibitor (NRTI) therapy compared the three drug combination of IDV plus 2 NRTIs (patient's choice) with the FOUR drug combination of efavirenz, plus IDV and two NRTIs. 180 patients had reached the 24 week analysis point, and results were reported on those patients in Geneva. This study, unlike some other efavirenz studies, was blinded.

Not surprisingly, the four drug combination was more effective than the three drug regimen at reducing viral load. After 24 weeks, 85.3% of the 4-drug patients had viral load levels under 400 copies, while 66.2% of patients on the 3-drug arm were <400 copies. This second number is less impressive than viral load reductions seen in other trials, a fact that could be attributed to the amount of NRTI experience among the patients. Benefit was seen in patients with baseline viral loads both above and below the100,000 copies per mL level, and both study arms saw significant increases in CD4 cell count, in the 100-120 cell range.

The study drugs were well-tolerated in both arms, but one must wonder whether a four-drug regimen (and its inherent adherence and side effect challenges) is an attractive option when some 2-drug regimens are showing equally impressive viral load reductions.




This article was provided by TheBodyPRO.com. Copyright Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:
http://www.thebody.com/content/art14668.html

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.